Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy

Martens, Thomas; Remaut, Katrien; Deschout, Hendrik; Engbersen, Johan F.J.; Hennink, Wim E.; Steenbergen, Mies J. van; Demeester, Jo; Braeckmans, Kevin

doi:10.1016/j.jconrel.2015.01.030

Cited by 124 publications

(75 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD44 is overexpressed in the surface of RPE and hence can be used as a key target for a number of drugs and gene-based therapeutics67, 68. In Martens׳s work, a nonviral polymeric gene complex with hyaluronic acid (HA) coating was demonstrated and shown to be efficiently taken up by RPE cells via the CD44-receptor mediated endocytosis, resulting in a high gene delivery and expression of green fluorescent protein (GFP) in the eye 69 .…”

Section: Nanosystems For Ocular Posterior Disease Therapymentioning

confidence: 99%

Nanotechnology-based strategies for treatment of ocular disease

Weng

Liu

Jin

et al. 2017

Acta Pharmaceutica Sinica B

270

176

View full text Add to dashboard Cite

Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal d iseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines.

show abstract

Section: Nanosystems For Ocular Posterior Disease Therapymentioning

confidence: 99%

Nanotechnology-based strategies for treatment of ocular disease

Weng

Liu

Jin

et al. 2017

Acta Pharmaceutica Sinica B

270

176

View full text Add to dashboard Cite

show abstract

“…Due to its well-tolerated and biocompatible nature, HA has been widely studied for biomedical applications including tissue engineering, drug delivery and molecular imaging (Li et al, 2015a;Martens et al, 2015). Importantly, HA is also utilized as a targeting ligand in drug carriers because it can effectively bind to the CD44 receptor, which is overexpressed in cancer cells Zhong et al, 2015), thus achieving active targeting for anticancer drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Self-assembled nanoparticles from hyaluronic acid–paclitaxel prodrugs for direct cytosolic delivery and enhanced antitumor activity

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…It is important to note that the anionic nature of the vitreous humour plays a key role in the charged particle distribution, limiting the diffusion of cationic nanoparticles in the posterior segment of the eye [34]. The transfection profile obtained with our positive charged vectors after intravitreous injection reveals that the incorporation of DX or HA polysaccharides to the formulations confers to the vectors stealth properties that likely favour their diffusion through the vitreous and also across the retina [35], facilitating the transfection of retinal layers distant from the injection site.…”

Section: Discussionmentioning

confidence: 91%